GlobeNewswire·May 22, 2026, 5:15 PM ET

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

Immix Biopharma, Inc. closed an underwritten registered offering of 16,778,524 common shares at $8.94 per share on May 22, 2026.
Net proceeds from the offering, after deducting underwriting discounts, commissions, & expenses, totaled approximately $140.65 million.
The financing included leading U.S. biotechnology institutional investors & mutual funds.
Morgan Stanley served as lead book-running manager, with BofA Securities acting as book-running manager.
LifeSci Capital, Mizuho, & Needham & Company acted as co-lead managers for the transaction.
The offering was conducted pursuant to a Form S-3 shelf registration statement filed with the SEC on January 9, 2026, & declared effective on January 22, 2026.
ImmixBio is a global leader in AL Amyloidosis with its lead candidate NXC-201, a CAR-T cell therapy currently in the NEXICART-2 study for relapsed/refractory AL Amyloidosis.
NXC-201 holds Breakthrough Therapy Designation, Regenerative Medicine Advanced Therapy designation, & Orphan Drug Designation from the FDA & EMA.